Skip to main content
main-content

Bone diseases

Fracture

07-11-2019 | Osteoporosis | News

Unfavorable risk–benefit profile of odanacatib for osteoporosis treatment

The cathepsin K inhibitor odanacatib reduces the incidence of fracture in postmenopausal women with osteoporosis, but at the cost of an increased risk for cardiovascular events, indicate findings from the LOFT trial.

Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

27-08-2019 | Osteoporosis | News | Article

Meta-analysis questions use of osteoporosis treatments to reduce mortality risk

Findings from a meta-analysis published in JAMA Internal Medicine indicate that drug treatments for osteoporosis, particularly bisphosphonates, are not associated with a significant reduction in overall mortality risk.

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

24-05-2019 | Rheumatoid arthritis | Highlight | News

Opioids, SSRIs, glucocorticoids implicated in RA fracture risk

US research shows that the use of opioids, selective serotonin reuptake inhibitors, or glucocorticoids may increase the risk for all types of osteoporotic fracture in patients with rheumatoid arthritis.

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

19-11-2018 | Osteoporosis | Article

Risk of subsequent fracture after prior fracture among older women

Balasubramanian A et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4732-1

No benefit of vitamin D supplementation for musculoskeletal health

The use of vitamin D supplements for maintaining or improving musculoskeletal health is not warranted, suggest the findings of an updated systematic review and meta-analysis.

08-10-2018 | Vitamin D | News

No benefit of vitamin D supplementation for musculoskeletal health

The use of vitamin D supplements for maintaining or improving musculoskeletal health is not warranted, suggest the findings of an updated systematic review and meta-analysis.

Zoledronate benefits postmenopausal women with osteopenia

Treatment with zoledronate once every 18 months significantly reduces the risk for nonvertebral or vertebral fragility fractures, compared with placebo, in postmenopausal women with osteopenia, study findings indicate.

02-10-2018 | Osteopenia | Highlight | News

Zoledronate benefits postmenopausal women with osteopenia

Treatment with zoledronate once every 18 months significantly reduces the risk for nonvertebral or vertebral fragility fractures, compared with placebo, in postmenopausal women with osteopenia, study findings indicate.

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

This systematic review and meta-analysis were performed with the aim to quantify the risk of hip fracture associated with proton pump inhibitor use [read more].
Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

29-08-2018 | Osteoporosis | Review | Article

Proton pump inhibitors’ use and risk of hip fracture: A systematic review and meta-analysis

Hussain S et al. Rheumatol Int 2018. doi: 10.1007/s00296-018-4142-x

07-08-2018 | Rheumatoid arthritis | News

Disease activity linked to osteoporotic fracture risk in RA patients

Patients with rheumatoid arthritis who have high cumulative disease activity and functional disability have an elevated 10-year risk for osteoporotic fracture, researchers report.

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

This study aimed to examine the relationship between medication persistence and fracture risk among female Medicare beneficiaries diagnosed with osteoporosis [read more].
Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

23-07-2018 | Osteoporosis | Article

Incidence, risk factors, and fracture healing of atypical femoral fractures: A multicenter case-control study

Lim SJ et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4640-4

20-07-2018 | Osteoporosis | Article

Incidence of subsequent fractures in the UK between 1990 and 2012 among individuals 50 years or older

van der Velde RY et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4636-0

18-07-2018 | Osteoporosis | Article

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

Liu J et al. Osteoporos Int 2018. doi: 10.1007/s00198-018-4630-6

Image Credits